Immix Biopharma, Inc. (IMMX)

IMMX Biotech / Pharma

BiotechSign Signal Grade

Signal Grade

18.1/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying

Dilution Risk

Clinical Activity

Short Interest

Pipeline Overview

Therapeutic Focus: Biotech / Pharmasrc

Clinical Trial Activity

Clinical Trial
(ClinicalTrials.gov aggregate)

1 Phase 1, 1 Phase 2

Trial Phase Breakdown

PubMed Publications

Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov

Dilution Risk

MEDIUM DILUTION RISK

159.8 months

Cash Runway Estimate

37/100

Dilution Score

40Warrant Risk

40Convertible Risk

60Offering Ability

Dilution score: 37/100 (MEDIUM), 159.8 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

25.76%

Float Shorted

5.1

Days to Cover

HIGH

Squeeze Risk

+8.0%

SI Change

INCREASING

Trend

10,390,288

Shares Short

Short interest: 25.76% of float, squeeze risk: HIGH

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference Mon, 05 Oct 2026 · Yahoo Finance
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study Mon, 05 Oct 2026 · Yahoo Finance
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock Wed, 30 Sep 2026 · Yahoo Finance
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock Tue, 29 Sep 2026 · Yahoo Finance
Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial Tue, 29 Sep 2026 · Yahoo Finance
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis Tue, 29 Sep 2026 · Yahoo Finance
Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run Tue, 21 Jul 2026 · Yahoo Finance
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet Thu, 18 Jun 2026 · Yahoo Finance

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Immix Biopharma, Inc..

Full IMMX Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.